These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 6883360)

  • 61. [Chemotherapy-radiotherapy association in the treatment of localized forms of Hodgkin's disease. Prognosis of polychemotherapy after three trials of M.O.P.P].
    Baillet F; Brun B; Mazeron JJ; Rochant H; Pinon G; Reyes F; Vernant JP; Pierquin B; Dreyfus B
    Nouv Rev Fr Hematol Blood Cells; 1977; 18(2):457-61. PubMed ID: 917834
    [TBL] [Abstract][Full Text] [Related]  

  • 62. MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease.
    Cimino G; Biti GP; Anselmo AP; Maurizi Enrici R; Bellesi GP; Bosi A; Cionini L; Mungai V; Papa G; Ponticelli P
    J Clin Oncol; 1989 Jun; 7(6):732-7. PubMed ID: 2715803
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy.
    da Cunha MF; Meistrich ML; Fuller LM; Cundiff JH; Hagemeister FB; Velasquez WS; McLaughlin P; Riggs SA; Cabanillas FF; Salvador PG
    J Clin Oncol; 1984 Jun; 2(6):571-7. PubMed ID: 6547167
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Possibilities of treatment of reduction in Hodgkin's disease. III. Can polychemotherapy when combined with radiotherapy of localised stages be reduced? (author's transl)].
    Teillet F; Delbrück H; Bayle-Weisgerber C; Asselain B; Lelièvre P; Bernard J
    Dtsch Med Wochenschr; 1981 May; 106(18):566-70. PubMed ID: 7215184
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Hodgkin's disease in children; treatment results with or without radiotherapy].
    van Bunningen BN; Dewit L; Bartelink H
    Ned Tijdschr Geneeskd; 1986 May; 130(20):928-9. PubMed ID: 3755223
    [No Abstract]   [Full Text] [Related]  

  • 66. Status and perspectives in chemotherapy of Hodgkin's disease.
    Frei E
    Arch Intern Med; 1973 Mar; 131(3):439-45. PubMed ID: 4739436
    [No Abstract]   [Full Text] [Related]  

  • 67. [Second tumor following Hodgkin's disease].
    Schmitt K; Tulzer W
    Padiatr Padol; 1984; 19(3):259-62. PubMed ID: 6548008
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Combination chemotherapy (MOPP) in 60 patients with Hodgkin's disease (five years results) (author's transl)].
    Lauria F; Baccarani M; Barbieri E; Fiacchini M; Gobbi M; Tura S; Baccarani M
    Haematologica; 1975 Mar; 60(1):73-84. PubMed ID: 806500
    [No Abstract]   [Full Text] [Related]  

  • 69. A comparison of nitrogen mustard, vincristine, procarbazine, and prednisone (MOPP) vs. nitrogen mustard in advanced Hodgkin's disease.
    Huguley CM; Durant JR; Moores RR; Chan YK; Dorfman RF; Johnson L
    Cancer; 1975 Oct; 36(4):1227-40. PubMed ID: 1175125
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Two cycles of MOPP and radiotherapy for stage III1A and stage III1B Hodgkin's disease.
    Henkelmann GC; Hagemeister FB; Fuller LM
    J Clin Oncol; 1988 Aug; 6(8):1293-302. PubMed ID: 3411342
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Late results of the treatment of advanced Hodgkin's disease by the MOPP/COPP programs (chlormethine or cyclophosphamide, vincristine, procarbazine and prednisone)].
    Błasińska-Morawiec M; Płuzańska A; Krykowski E; Robak T; Mrówka I
    Pol Arch Med Wewn; 1991 Oct; 86(4):274-80. PubMed ID: 1813880
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The MOPP controversy.
    DiBiasio AG
    Eye Ear Nose Throat Mon; 1972 Dec; 51(12):459-60. PubMed ID: 4637961
    [No Abstract]   [Full Text] [Related]  

  • 73. Feasibility of different combinations of chemotherapy (6 MOPP) plus radiotherapy in Hodgkin's disease.
    Volterrani F; Zucali R; Sigurtà D; Severini A; Santoro A
    Tumori; 1979 Dec; 65(6):729-41. PubMed ID: 543016
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hodgkin's disease, intracranial involvement. Report of a case and review of the literature.
    Vera R; Enriquez R; Papac R
    Am J Clin Oncol; 1985 Feb; 8(1):73-6. PubMed ID: 3838852
    [TBL] [Abstract][Full Text] [Related]  

  • 75. MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long-term results of the prospective trial H72 (1972-1976, 334 patients).
    Andrieu JM; Dana M; Desprez-Curely JP; Jacquillat C; Weil M
    Hematol Oncol; 1985; 3(4):219-31. PubMed ID: 3841333
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Semantics and the chemotherapy of Hodgkin's disease--resistance is not relapse: alternative chemotherapy lacks effectiveness for disease not totally responsive to initial MOPP treatment.
    Coleman M; Friedlander RJ
    Cancer Invest; 1988; 6(2):237-9. PubMed ID: 3288299
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dilemmas in the treatment of Hodgkin's disease.
    Somers R; Lutz-Honders M; Cleton FJ; van Dongen JA
    Folia Med Neerl; 1971; 14(2):77-88. PubMed ID: 4934404
    [No Abstract]   [Full Text] [Related]  

  • 78. Twenty years of MOPP therapy for Hodgkin's disease.
    Longo DL; Young RC; Wesley M; Hubbard SM; Duffey PL; Jaffe ES; DeVita VT
    J Clin Oncol; 1986 Sep; 4(9):1295-306. PubMed ID: 3528400
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Splenectomy effects on chemotherapy in Hodgkin's disease.
    Panettiere F; Coltman CA
    Arch Intern Med; 1973 Mar; 131(3):362-6. PubMed ID: 4688035
    [No Abstract]   [Full Text] [Related]  

  • 80. A rare opportunity to observe aspects of the natural history of untreated Hodgkin's disease.
    Haines IE; Schwarz MA
    Med J Aust; 1986 Jun; 144(12):652-4. PubMed ID: 3754928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.